Datapoint: Amgen Shores Up Otezla Patent Until 2028

In a victory against Sandoz and Zydus Pharmaceuticals, Amgen last week won a patent case protecting its blockbuster psoriasis drug Otezla from generic competition until 2028. For the treatment of psoriasis, Otezla holds covered or better status for 69% of all insured lives under the pharmacy benefit. It is not covered for 9.5% of lives.

SOURCE: MMIT Analytics, as of 9/22/21

0

0

0 Comments

0

0

• Datapoint